RE:RE:RE:Q3 on sedsrMaybe Glen needs to make a couple of calls to some suitors. We have some products of unknown potential that they may be interested in.
Tilray comes to mind and they are working on a German footprint. They also have kept up acquisitions of companies of potential although they may already have whatever it is that NU is offering.
Or maybe they should just go for Cryopharm who have a nice looking stable of products if they are still a viable company.
Nu's problem is a negligile history of unsuccessful products and deals despite the potential and nice looking skus and I suspect, not enough angels$$$$.